top of page

Cancer Beyond Mutations: Epigenetic Regulation in Tumor Development, Progression, and Therapeutic Resistance

Anagha Chittabathini
21/11/26

Cancer has historically been defined as a genetic disease driven by the accumulation of mutations that alter oncogenes, tumor suppressor genes, DNA repair pathways, and other regulators of cellular homeostasis. Although this genetic model remains central to modern oncology, it does not fully account for the phenotypic diversity, plasticity, and therapeutic adaptability observed in tumors. Epigenetic regulation provides an additional layer of biological control by modulating gene activity without altering the underlying DNA sequence. Through mechanisms such as DNA methylation, histone modification, chromatin remodeling, and non-coding RNA regulation, epigenetic processes determine whether genomic regions remain transcriptionally active, repressed, or poised for activation. In normal tissues, these mechanisms are essential for the development, differentiation, and maintenance of cell identity. In cancer, however, epigenetic dysregulation can silence tumor suppressor pathways, activate oncogenic transcriptional programs, promote cellular plasticity, and contribute to treatment resistance. Importantly, many epigenetic alterations are dynamic and potentially reversible, making the cancer epigenome an appealing yet complex therapeutic target. This review summarizes the major mechanisms of epigenetic regulation, examines their roles in tumor development and progression, and discusses how epigenetic plasticity contributes to therapeutic resistance. Finally, it considers current and emerging approaches to epigenetic therapy and highlights the need for improved biomarkers and integrated molecular profiling to guide future clinical applications.

bottom of page